Peripherally Inserted Central Catheter Market Size, Share, & Trends Analysis | Global | 2026-2032 | Includes: Single, Double, and 1 Other Catheter

Global Peripherally Inserted Central Catheter Market Report to 2032

The global peripherally inserted central catheter market was valued at approximately $838 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 3.3%, reaching $1.1 billion by 2032.

This report covers the global market for peripherally inserted central catheters (PICCs), including single-lumen, double-lumen, and triple-lumen devices.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by new PICC technologies, expanded use of PICCs in place of CVCs and PIVCs, and continued adoption of power-injectable, valved, antimicrobial, and antithrombogenic devices. However, infection concerns and shortages of trained nursing personnel continue to limit stronger adoption.

Market Overview

The global PICC market includes peripherally inserted central catheters used to provide medium- to long-term vascular access through a peripheral vein, with the catheter tip positioned centrally.

PICCs are used across hospital, outpatient, oncology, infusion, and chronic care settings. They are commonly selected when patients require IV access for a week or longer, or when central access is needed without placing a traditional CVC.

The market is segmented by lumen type, device type, kit type, and valve type. This includes single-, double-, and triple-lumen devices, power-injectable and non-power-injectable PICCs, tip-placement and conventional kits, and valved and non-valved PICCs.

Product differentiation and incremental innovation continue to shape competition. Manufacturers have expanded portfolios to include valved, power-injectable, multi-lumen, antimicrobial, and antithrombogenic configurations. These designs are intended to improve clinical performance, reduce complications, broaden use cases, and support modern vascular access protocols.

Market Drivers

New Technologies

New technologies are a major driver in the PICC market. Manufacturers are using product differentiation to support premium pricing and defend ASPs in a competitive vascular access category.

The market has already seen the development of valved PICCs, power-injectable PICCs, triple-lumen PICCs, antimicrobial PICCs, and antithrombogenic PICCs. These products help address clinical needs such as infection prevention, thrombus reduction, imaging compatibility, and multi-therapy access.

New technologies typically command higher selling prices than standard PICCs. This helps prevent overall ASP decline and supports market value growth, even when unit volume gains are moderate.

Ongoing improvements to existing PICC designs are also expected to support adoption. Better designs can reduce infection and complication rates, improve ease of insertion, and increase patient comfort.

Expansion of PICC Use

The expansion of PICC use is another important driver. PICC volume growth depends on the use of PICCs in situations where a CVC or PIVC may previously have been placed.

During hospitalization, most patients receive some kind of IV catheter. Compared with CVCs and PIVCs, the volume of PICCs placed remains lower, leaving room for penetration into adjacent vascular access categories.

PICCs are increasingly being placed at the start of treatment for patients who may require IV access for a week or longer. Although PICCs are more expensive than PIVCs, they do not need to be replaced every 72 hours, which can save time and reduce total care burden.

PICCs are also replacing CVCs in some chronic vascular access cases because they are associated with lower infection rates. With triple-lumen PICCs and antimicrobial technology becoming more common, PICCs are expected to continue capturing selected cases from the CVC market.

Nurse-Led Placement and Workflow Efficiency

One of the practical advantages of PICCs is that they can often be placed by trained nurses at the bedside. This reduces the need for physician placement and can lower procedural costs.

Bedside placement also supports workflow efficiency. It can reduce delays, avoid operating room or interventional suite time in selected cases, and allow hospitals to manage vascular access needs more flexibly.

As more hospitals build vascular access teams and nurse-led placement programs, PICC adoption can increase. This is especially relevant in settings where reducing physician workload, improving access timing, and lowering procedural cost are priorities.

Market Limiters

Infection Rate

Infection risk remains an important limiter for PICCs. A key concern for all catheter types is catheter-related infection, which can create major clinical and financial consequences for hospitals.

A catheter-related infection can cost hospitals an average of $25,000 or more. While PICCs generally have lower infection rates than CVCs, there is ongoing debate about how often PICCs should be used when less risky PIVCs could be used instead.

This concern can limit PICC use in patients who only require short-term access or who can be treated with a simpler peripheral device. The rise of antimicrobial and antithrombogenic PICCs may reduce the effect of this limiter, but infection risk will remain an important factor in device selection.

Shortage of Nursing Personnel

A shortage of nursing personnel can limit PICC placement. One advantage of PICCs is that trained nurses can place them at bedside, but this advantage depends on having enough trained professionals available.

When fewer nurses are available, there may be fewer staff members able to place PICCs efficiently. In those cases, another vascular access device, such as a PIVC, may be inserted instead because it is easier and quicker to place.

This limiter is especially relevant in facilities facing staffing pressure or limited vascular access team capacity. Without enough trained personnel, PICC adoption may be slower than clinical demand would suggest.

Competition from PIVCs and CVCs

PICCs compete with both PIVCs and CVCs. While PICCs can replace some use cases, PIVCs and CVCs remain well suited for specific applications.

PIVCs are easier, faster, and less expensive to place, making them appropriate for many short-term access needs. CVCs remain necessary in critical care cases requiring higher flow rates or more urgent central access.

Because each catheter type has a defined role, PICCs cannot fully replace either category. This limits the total addressable market and keeps PICC growth dependent on appropriate patient selection.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers peripherally inserted central catheters segmented by lumen type, device type, kit type, and valve type, including advanced material devices with antimicrobial or antithrombogenic properties.

Markets Covered and Segmentation

Peripherally Inserted Central Catheter Market

• Lumen type: Single, double, and triple.

Single-lumen PICCs are used when one access channel is sufficient. Double-lumen and triple-lumen PICCs support more complex therapy requirements where multiple medications, infusions, or access needs must be managed.

• Device type: Power-injectable and non-power-injectable.

Power-injectable PICCs are designed to withstand higher pressure during contrast-enhanced imaging workflows. Non-power-injectable PICCs remain relevant for standard infusion and vascular access needs.

Power-injectable PICCs are further segmented by material type into advanced material devices and conventional devices. Advanced material devices may include antimicrobial or antithrombogenic properties, while conventional devices do not include these enhancements.

• Kit type: Tip-placement kit and conventional kit.

Tip-placement kits include disposables used with a tip-placement system. Conventional kits include standard placement components without these systems.

• Valve type: Valved PICC and non-valved PICC.

Valved PICCs are designed to support flow control and reduce certain complications, while non-valved PICCs remain widely used depending on physician preference, product availability, and cost considerations.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

Competitive Analysis

Becton Dickinson holds a dominant position in the global PICC market, supported by its extensive portfolio and tip-confirmation technology. The company bundles vascular access products and actively invests in education and training, reinforcing its position with both interventional radiologists and nurses.

BD's portfolio includes POWERPICC(R), POWERPICC(R) Solo(R), Poly RADPICC(R), Per-Q-Cath(R), Poly Per-Q-Cath(R), and the newer POWERPICC(R) Provena. POWERPICC(R) Provena is marketed as having a smaller diameter, while Solo(R) has replaced older silicone PICC lines.

BD also sells the majority of triple-lumen PICCs and generates significant revenue from tip-guidance PICC kits used with its Sherlock tip-placement systems. The company views the growing number of nurse-placed PICCs and emerging market adoption as key growth drivers.

Teleflex is the second-largest player in the PICC market, having inherited Arrow International's product line. Its power-injectable PICCs and triple-lumen variants have performed strongly, although not at the same level as BD's portfolio.

Teleflex's ARROW(R) PICCs with Chlorag+ard(R) Technology are prominent antimicrobial and antithrombotic devices. The company's strong position in the CVC market may also support its expansion across other vascular access segments.

Vygon holds a stable position in the PICC market, particularly in Europe. Its PICC products emphasize controlled catheter materials, reliable insertion performance, and alignment with standardized vascular access practices. The company maintains share through consistent hospital adoption rather than rapid portfolio expansion.

Technology and Practice Trends

Power-Injectable PICCs

Power-injectable PICCs are increasingly important because they support contrast-enhanced imaging workflows. These devices provide greater clinical flexibility and can reduce the need for additional vascular access placement.

Their higher ASPs support market value growth.

Antimicrobial and Antithrombogenic Materials

Advanced material PICCs are designed to reduce infection and thrombus-related complications. These features support differentiation and may improve clinical confidence.

As complication reduction remains a major focus, these technologies are expected to remain important.

Tip-Placement Systems

Tip-placement systems and related kits are becoming more important in PICC placement workflows. These systems help support accurate catheter tip positioning and reduce uncertainty during insertion.

BD's Sherlock tip-placement systems are an example of this trend.

Multi-Lumen PICCs

Triple-lumen and double-lumen PICCs support more complex treatment needs. These devices allow multiple therapies or infusions to be managed through one catheter.

Multi-lumen adoption supports higher ASPs and broadens PICC use in more complex patients.

Nurse-Led Placement

Nurse-led bedside placement remains a major advantage for PICCs. It can reduce physician involvement and improve workflow efficiency.

However, adoption depends on the availability of trained nursing personnel and vascular access teams.

PICCs Replacing Selected CVC Use

PICCs are increasingly used in some chronic access cases where CVCs were previously placed. Their lower infection rate compared with CVCs supports this shift.

However, CVCs remain important in critical care cases requiring high flow rates.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global PICC market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• How are single-lumen, double-lumen, and triple-lumen PICCs performing?
• What role do power-injectable PICCs play in market value growth?
• How are antimicrobial and antithrombogenic materials affecting product differentiation?
• How are PICCs replacing selected CVC and PIVC use cases?
• Why is nurse-led bedside placement important to PICC adoption?
• How do infection concerns and nursing shortages limit market growth?
• Which companies lead the global PICC market?
• How are BD, Teleflex, and Vygon positioned across power-injectable, multi-lumen, advanced material, and tip-placement PICC categories?

The Global Peripherally Inserted Central Catheter Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand PICC technology adoption, and support commercial planning in the global PICC market.